About
Mark Iwicki is a U.S. biopharmaceutical executive who became Chief Executive Officer of Inhibikase Therapeutics effective February 14, 2025. He previously served as CEO of KALA BIO, Civitas Therapeutics, Sunovion Pharmaceuticals, and Blend Therapeutics, and earlier was President and COO of Sepracor. He also serves as a board chair/director across several biotech companies, giving him significant operating and governance influence in the sector.
Areas of interest
biotechbiopharmadrug developmentdrug commercializationautoimmune diseaseinflammatory diseasecardiovascular diseasepulmonary arterial hypertensioncorporate governance